Perspective on current and emerging drugs in the treatment of acute and chronic toxoplasmosis
| Autor: | Paula J. Lapinskas, Ruben R. Ben-Harari |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Antiprotozoal Agents Protozoan Proteins 030209 endocrinology & metabolism 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine medicine Animals Humans Intensive care medicine Human society business.industry Calcium-Binding Proteins General Medicine medicine.disease Toxoplasmosis United States Tetrahydrofolate Dehydrogenase Chronic disease Pyrimethamine Acute Disease Chronic Disease Folic Acid Antagonists Tetrahydrofolate dehydrogenase business Protein Kinases Toxoplasma |
| Zdroj: | Postgraduate medicine. 131(8) |
| ISSN: | 1941-9260 |
| Popis: | No new drugs for treatment of toxoplasmosis have been approved in over 60 years, despite the burden of toxoplasmosis on human society. The small selection of effective drugs is limited by important side effects, often limiting patient use. This perspective highlights promising late-stage drug candidates in the treatment of toxoplasmosis. Presently, drugs target the tachyzoite form of the parasite |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|